Amneal director reports trades in 168,573 shares

BUCHI J KEVIN reported disposition transactions in this Form 4 filing.

Rhea-AI Filing Summary

BUCHI J KEVIN reported disposition transactions in this Form 4 filing.

Amneal Pharmaceuticals, Inc. director Kevin J. Buchi reported a derivative exercise/conversion transaction involving 168,573 shares of Class A Common Stock on 2026-08-11 at a weighted average price of $17.18 per share. According to the footnote, the shares were sold in multiple trades between $17.07 and $17.31 per share. Following this activity, 93,499 shares are held indirectly by a trust and a separate holding entry shows 75,077 shares held directly.

Insider Trade Summary

Exercise: 168,573 shares

Exercise 2 txns

Insider BUCHI J KEVIN

Role Director

Type	Security	Shares	Price	Value
Exercise	Class A Common Stock F1	168,573	$17.18	$2.90M
holding	Class A Common Stock	--	--	--

Holdings After Transaction: Class A Common Stock — 93,499 shares (Indirect, By Trust); Class A Common Stock — 75,077 shares (Direct)

Footnotes (1)

1. F1. The price included in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $17.07 to $17.31 per share, inclusive. The Reporting Person undertakes to provide to Amneal Pharmaceuticals, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in the footnote.

Key Figures

Shares in reported transaction: 168,573 shares Weighted average price: $17.18 per share Indirect holdings after transaction: 93,499 shares +1 more

4 metrics

Shares in reported transaction 168,573 shares Class A Common Stock derivative exercise/conversion on 2026-08-11

Weighted average price $17.18 per share Price for 168,573 shares, with trades from $17.07 to $17.31

Indirect holdings after transaction 93,499 shares Class A Common Stock held indirectly by trust following the transaction

Direct holdings after transaction 75,077 shares Class A Common Stock held directly in separate holding entry

Key Terms

weighted average price, Class A Common Stock, indirect ownership

3 terms

weighted average price financial

"The price included in column 4 is a weighted average price."

Weighted average price is the average price of a security where each trade or component is counted according to its size, so bigger trades pull the average more than smaller ones. Think of it like calculating the average cost of a grocery haul where items you bought more of have greater influence on the final per-item cost. Investors use it to understand the true average price paid or received, judge execution quality, and compare trading performance against market movement.

Class A Common Stock financial

"security_title: Class A Common Stock for the reported transaction."

Class A common stock is a category of a company’s shares that carries a specific set of ownership rights—most commonly defined voting power and claims on dividends—set out in the company’s charter. For investors it matters because the class determines how much influence you have over corporate decisions, the share’s likely dividend and trading behavior, and how it compares in value to other share classes, like choosing a particular seat with different privileges at the company’s decision-making table.

indirect ownership financial

"Indirect ownership is indicated as By Trust for 93,499 shares."

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What transaction did AMRX director Kevin J. Buchi report on this Form 4?

Kevin J. Buchi reported a derivative exercise/conversion involving 168,573 shares of Amneal Class A Common Stock on 2026-08-11, with the transaction coded as an exercise or conversion of a derivative security and marked as a disposition.

At what prices were the AMRX shares traded in Buchi’s reported transaction?

The weighted average price reported was $17.18 per share. The related footnote states the 168,573 shares were sold in multiple transactions at prices ranging from $17.07 to $17.31 per share, inclusive.

How many AMRX shares does Kevin J. Buchi hold indirectly after the reported transaction?

After the reported transaction, 93,499 shares of Amneal Class A Common Stock are held indirectly by a trust associated with Kevin J. Buchi, as shown by the indirect ownership entry on the Form 4.

What are Kevin J. Buchi’s direct holdings of AMRX shares after this Form 4 activity?

A separate holding line on the Form 4 shows 75,077 shares of Amneal Class A Common Stock held directly by Kevin J. Buchi following the reported 2026-08-11 transactions, in addition to his indirect trust holdings.

Does the AMRX Form 4 note that the reported prices are weighted averages?

Yes. A footnote explains that the $17.18 figure is a weighted average price, and that the 168,573 shares were sold in multiple transactions between $17.07 and $17.31, with trade-by-trade detail available on request.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 08/13/2026 - 04:21 PM Accepted by SEC EDGAR 08/13/2026 - 04:21 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

BUCHI J KEVIN

(Last) (First) (Middle)

C/O AMNEAL PHARMACEUTICALS, INC.

400 CROSSING BOULEVARD

(Street)

BRIDGEWATER NEW JERSEY 08807

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Amneal Pharmaceuticals, Inc. [ AMRX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
08/11/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Class A Common Stock	08/11/2026		M		168,573	D	$17.18(1)	93,499	I	By Trust
Class A Common Stock								75,077	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The price included in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $17.07 to $17.31 per share, inclusive. The Reporting Person undertakes to provide to Amneal Pharmaceuticals, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in the footnote.

Remarks:

	/s/ Denis Butkovic, Attorney-in-Fact	08/13/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)